NanoSphere Health Sciences Inc. (NSHSF)
USD 0.0
(-96.2%)
USD 0.0
(-96.2%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -9268.34 USD | 83.15% |
| 2022 | -55.01 Thousand USD | 57.93% |
| 2021 | -130.75 Thousand USD | -315.12% |
| 2020 | 60.78 Thousand USD | -47.6% |
| 2019 | 116 Thousand USD | 154.82% |
| 2018 | -211.62 Thousand USD | 94.28% |
| 2017 | -3.7 Million USD | -269.01% |
| 2016 | -1 Million USD | -520.02% |
| 2015 | -161.78 Thousand USD | -143.13% |
| 2014 | -66.54 Thousand USD | -392.26% |
| 2013 | -13.51 Thousand USD | 99.19% |
| 2012 | -1.66 Million USD | 68.44% |
| 2011 | -5.27 Million USD | -11445.05% |
| 2010 | -45.73 Thousand USD | 90.61% |
| 2009 | -486.93 Thousand USD | -548.26% |
| 2008 | -75.11 Thousand USD | 91.97% |
| 2007 | -935.26 Thousand USD | -227.5% |
| 2006 | -285.57 Thousand USD | 9.55% |
| 2005 | -315.74 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 8068.00 USD | 199.4% |
| 2024 Q1 | -8117.62 USD | 12.42% |
| 2023 FY | -9268.34 USD | 83.15% |
| 2023 Q1 | -33.59 Thousand USD | 38.93% |
| 2023 Q2 | -26.19 Thousand USD | 22.04% |
| 2023 Q3 | -11.36 Thousand USD | 56.59% |
| 2023 Q4 | -9268.34 USD | 18.48% |
| 2022 Q2 | -88.45 Thousand USD | 28.92% |
| 2022 FY | -55.01 Thousand USD | 57.93% |
| 2022 Q4 | -55.01 Thousand USD | 9.45% |
| 2022 Q3 | -60.75 Thousand USD | 31.32% |
| 2022 Q1 | -124.44 Thousand USD | 4.83% |
| 2021 FY | -130.75 Thousand USD | -315.12% |
| 2021 Q2 | 34.81 Thousand USD | -17.86% |
| 2021 Q3 | -148.89 Thousand USD | -527.66% |
| 2021 Q1 | 42.38 Thousand USD | -30.27% |
| 2021 Q4 | -130.75 Thousand USD | 12.18% |
| 2020 Q4 | 60.78 Thousand USD | -21.21% |
| 2020 Q1 | 132.44 Thousand USD | 14.17% |
| 2020 Q2 | 103.8 Thousand USD | -21.63% |
| 2020 Q3 | 77.14 Thousand USD | -25.68% |
| 2020 FY | 60.78 Thousand USD | -47.6% |
| 2019 Q1 | -432.6 Thousand USD | -104.42% |
| 2019 FY | 116 Thousand USD | 154.82% |
| 2019 Q2 | -99.24 Thousand USD | 77.06% |
| 2019 Q3 | 33.9 Thousand USD | 134.16% |
| 2019 Q4 | 116 Thousand USD | 242.14% |
| 2018 Q4 | -211.62 Thousand USD | -81.17% |
| 2018 FY | -211.62 Thousand USD | 94.28% |
| 2018 Q3 | -116.81 Thousand USD | 89.05% |
| 2018 Q2 | -1.06 Million USD | 53.41% |
| 2018 Q1 | -2.28 Million USD | 38.15% |
| 2017 FY | -3.7 Million USD | -269.01% |
| 2017 Q3 | -813.29 Thousand USD | -6.86% |
| 2017 Q2 | -761.07 Thousand USD | 12.84% |
| 2017 Q1 | -873.19 Thousand USD | 13.0% |
| 2017 Q4 | -3.7 Million USD | -355.14% |
| 2016 FY | -1 Million USD | -520.02% |
| 2016 Q1 | -152.63 Thousand USD | 5.93% |
| 2016 Q3 | -1.06 Million USD | -886.62% |
| 2016 Q2 | -108.19 Thousand USD | 29.12% |
| 2016 Q4 | -1 Million USD | 5.97% |
| 2015 Q1 | -58.97 Thousand USD | 11.77% |
| 2015 Q3 | -171.91 Thousand USD | -482.04% |
| 2015 Q4 | -162.25 Thousand USD | 5.62% |
| 2015 FY | -161.78 Thousand USD | -143.13% |
| 2015 Q2 | -29.53 Thousand USD | 49.91% |
| 2014 Q3 | -78.92 Thousand USD | -685.65% |
| 2014 FY | -66.54 Thousand USD | -392.26% |
| 2014 Q4 | -66.84 Thousand USD | 15.31% |
| 2014 Q1 | -11.34 Thousand USD | 16.05% |
| 2014 Q2 | -10.04 Thousand USD | 11.47% |
| 2013 Q4 | -13.51 Thousand USD | 45.69% |
| 2013 Q3 | -24.88 Thousand USD | 83.44% |
| 2013 Q2 | -150.32 Thousand USD | 80.74% |
| 2013 Q1 | -780.64 Thousand USD | 53.15% |
| 2013 FY | -13.51 Thousand USD | 99.19% |
| 2012 Q3 | -2.53 Million USD | 30.03% |
| 2012 Q1 | -4.45 Million USD | 15.64% |
| 2012 FY | -1.66 Million USD | 68.44% |
| 2012 Q4 | -1.66 Million USD | 34.33% |
| 2012 Q2 | -3.62 Million USD | 18.58% |
| 2011 Q2 | -8.21 Million USD | -91.79% |
| 2011 Q3 | -6.47 Million USD | 21.15% |
| 2011 FY | -5.27 Million USD | -11445.05% |
| 2011 Q1 | -4.28 Million USD | -9267.48% |
| 2011 Q4 | -5.27 Million USD | 18.51% |
| 2010 FY | -45.73 Thousand USD | 90.61% |
| 2010 Q3 | -11.27 Thousand USD | 97.27% |
| 2010 Q1 | -474.48 Thousand USD | 2.56% |
| 2010 Q4 | -45.73 Thousand USD | -305.46% |
| 2010 Q2 | -413.04 Thousand USD | 12.95% |
| 2009 Q2 | -1819.20 USD | 99.26% |
| 2009 Q1 | -245.88 Thousand USD | -227.34% |
| 2009 FY | -486.93 Thousand USD | -548.26% |
| 2009 Q3 | -277.9 Thousand USD | -15176.06% |
| 2009 Q4 | -486.93 Thousand USD | -75.22% |
| 2008 Q3 | -151.1 Thousand USD | 44.58% |
| 2008 Q1 | -371.4 Thousand USD | 60.29% |
| 2008 Q4 | -75.11 Thousand USD | 50.29% |
| 2008 FY | -75.11 Thousand USD | 91.97% |
| 2008 Q2 | -272.67 Thousand USD | 26.58% |
| 2007 Q1 | -261.23 Thousand USD | 8.52% |
| 2007 Q3 | -2.97 Million USD | 30.63% |
| 2007 Q4 | -935.26 Thousand USD | 68.55% |
| 2007 FY | -935.26 Thousand USD | -227.5% |
| 2007 Q2 | -4.28 Million USD | -1541.15% |
| 2006 Q3 | -305.62 Thousand USD | 1.31% |
| 2006 Q1 | -309.3 Thousand USD | 2.04% |
| 2006 FY | -285.57 Thousand USD | 9.55% |
| 2006 Q4 | -285.57 Thousand USD | 6.56% |
| 2006 Q2 | -309.68 Thousand USD | -0.12% |
| 2005 FY | -315.74 Thousand USD | 0.0% |
| 2005 Q3 | -346.83 Thousand USD | 0.0% |
| 2005 Q4 | -315.74 Thousand USD | 8.96% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Evofem Biosciences, Inc. | 42.79 Million USD | 100.022% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 101.489% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 96.287% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 54.585% |
| Qrons Inc. | 351.42 Thousand USD | 102.637% |
| Rebus Holdings, Inc. | 305 Thousand USD | 103.039% |
| Skye Bioscience, Inc. | -5.72 Million USD | 99.838% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 99.853% |
| Adynxx, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 100.021% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | 146.652% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 100.164% |
| Burzynski Research Institute, Inc. | -1310.00 USD | -607.507% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 100.059% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 100.225% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 102.306% |
| SQZ Biotechnologies Company | -36.23 Million USD | 99.974% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 100.413% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 101.0% |
| Mesoblast Limited | 55.85 Million USD | 100.017% |
| Marizyme, Inc. | 18.56 Million USD | 100.05% |
| Genus plc | 190.6 Million USD | 100.005% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 100.415% |
| Pharming Group N.V. | 109.8 Million USD | 100.008% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 101.077% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 100.764% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 101.363% |
| ContraFect Corporation | -6.02 Million USD | 99.846% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 106.884% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 100.802% |
| IMV Inc. | 7.67 Million USD | 100.121% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 100.168% |
| MultiCell Technologies, Inc. | 90.04 USD | 10393.581% |
| ONE Bio Corp. | 9.04 Million USD | 100.103% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 98.737% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 100.072% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | 100.678% |
| Q BioMed Inc. | 4.06 Million USD | 100.228% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 100.03% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 100.92% |
| Biomind Labs Inc. | 711.4 Thousand USD | 101.303% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 100.015% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 100.464% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 100.072% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 102.577% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 106.63% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 100.421% |
| GB Sciences, Inc. | 1.74 Million USD | 100.53% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 94.957% |
| HST Global, Inc. | 96.79 Thousand USD | 109.575% |
| CSL Limited | 10.52 Billion USD | 100.0% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 104.494% |
| Halberd Corporation | 144.72 Thousand USD | 106.404% |
| Enzolytics Inc. | 981.65 Thousand USD | 100.944% |
| Agentix Corp. | 37.63 Thousand USD | 124.63% |
| Resverlogix Corp. | 6.45 Million USD | 100.144% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 98.623% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -2.02 Billion USD | 100.0% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 99.98% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 100.131% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 100.342% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 99.895% |
| AVAX Technologies, Inc. | -5.9 Million USD | 99.843% |
| Zenith Capital Corp. | 10.06 Thousand USD | 192.094% |
| Genscript Biotech Corporation | -1.06 Billion USD | 99.999% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 104.624% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 100.388% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 105.634% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 49.403% |
| Kadimastem Ltd | -253.1 Thousand USD | 96.338% |
| Helix BioMedix, Inc. | -2.57 Million USD | 99.639% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 100.046% |
| BioStem Technologies, Inc. | 4.47 Million USD | 100.207% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 104.605% |
| LadRx Corporation | -2.03 Million USD | 99.545% |
| Cell Source, Inc. | 9.23 Million USD | 100.1% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 101.459% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 101.459% |
| NovAccess Global Inc. | 2.17 Million USD | 100.425% |
| Affymax, Inc. | -5.59 Million USD | 99.834% |
| Itoco Inc. | 228.3 Thousand USD | 104.06% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 106.816% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 100.187% |
| Mobile Lads Corp. | 484.23 Thousand USD | 101.914% |
| CytoDyn Inc. | 20.26 Million USD | 100.046% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | -1332.51% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 100.12% |
| SYBLEU INC | 473.71 Thousand USD | 101.957% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 100.208% |
| International Stem Cell Corporation | 2.59 Million USD | 100.358% |
| Bioxytran, Inc. | 1.89 Million USD | 100.488% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 114.85% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 100.425% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 100.27% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 100.108% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 101.2% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 99.259% |
| Neutra Corp. | 52.18 Thousand USD | 117.76% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 99.628% |
| PureTech Health plc | -167.19 Million USD | 99.994% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 96.216% |
| IXICO plc | -4.44 Million USD | 99.791% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 100.07% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 100.017% |
| CSL Limited | 10.52 Billion USD | 100.0% |
| Cellectis S.A. | -43.81 Million USD | 99.979% |